Study of the Week: Method for Predicting Severe Cardiac Events Following Renal Cell Carcinoma Treatment
source: pixabay.com

Study of the Week: Method for Predicting Severe Cardiac Events Following Renal Cell Carcinoma Treatment

Welcome to Study of the Week from Patient Worthy. In this segment, we select a study we posted about from the previous week that we think is of particular interest…

Continue Reading Study of the Week: Method for Predicting Severe Cardiac Events Following Renal Cell Carcinoma Treatment

Doctors Receive Nobel Prize for Development in Renal Cell Carcinoma Treatment

Research by three doctors provided a basis for tyrosine kinase inhibitors (TKI) and offered advancements in treatment for renal cell carcinoma (RCC) patients. Two such TKIs, sunitinib and sorafenib, remain…

Continue Reading Doctors Receive Nobel Prize for Development in Renal Cell Carcinoma Treatment
ICYMI: Trial Begins to Evaluate Savolitinib and IMFINZI for Renal Cell Carcinoma
Photo by Robina Weermeijer on Unsplash

ICYMI: Trial Begins to Evaluate Savolitinib and IMFINZI for Renal Cell Carcinoma

According to a news release, researchers from biopharmaceutical company HUTCHMED and pharmaceutical company AstraZeneca launched, at the onset of November 2021, the Phase 3 SAMETA clinical trial. During the trial,…

Continue Reading ICYMI: Trial Begins to Evaluate Savolitinib and IMFINZI for Renal Cell Carcinoma
Study: Tivozanib As a Treatment for Advanced Renal Cell Carcinoma
Photo by Robina Weermeijer on Unsplash

Study: Tivozanib As a Treatment for Advanced Renal Cell Carcinoma

Recently the Kidney Cancer Association held its International Kidney Cancer Symposium, where medical professionals and other industry members come together to share ideas and push for innovative research and treatments…

Continue Reading Study: Tivozanib As a Treatment for Advanced Renal Cell Carcinoma

Merck’s Keytruda in Combination with Pfizer’s Inlyta Significantly Improved Overall Survival and Progression-Free Survival in Therapy for Metastatic or Advanced Renal Cell Carcinoma

  The treatment of metastatic renal cell carcinoma (RCC) has evolved over the last ten years and investigators now look towards combination therapies to improve response rates and durability for…

Continue Reading Merck’s Keytruda in Combination with Pfizer’s Inlyta Significantly Improved Overall Survival and Progression-Free Survival in Therapy for Metastatic or Advanced Renal Cell Carcinoma